Alecensa increases OS rate in ALK-positive NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III ALEX study demonstrated an increased five-year survival rate with Alecensa (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase-positive non-small cell lung cancer.

These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO annual meeting on May 29.

“Importantly, these data show clinically meaningful benefit in people with or without central nervous system metastases,” Levi Garraway, chief medical officer and head of global product development at Roche, said in a statement.

The updated results from the ALEX study show a five-year survival rate of 62.5% (95% CI: 54.3-70.8) in the Alecensa treatment group, versus 45.5% (95% CI: 33.6-57.4) with crizotinib. Despite longer median treatment duration, the safety profile of Alecensa remains favourable and consistent with previous data, with no new safety signals identified. The overall survival data, which are not yet mature, show a benefit in patients with CNS metastases at baseline (42% reduction in the risk of death versus crizotinib (95% CI: 0.34-1.00)), as well as in those without CNS metastases at baseline (24% reduction in the risk of death versus crizotinib (95% CI: 0.45-1.26)).

These data follow on from the final, mature progression-free survival data from the ALEX study, presented at the European Society for Medical Oncology congress in September 2019, which demonstrated a reduced risk of disease worsening or death by 57% (hazard ratio=0.43, 95% CI: 0.32–0.58) with Alecensa, versus crizotinib, in ALK-positive NSCLC.2 The updated data confirm the superior efficacy and tolerability of Alecensa in comparison to crizotinib.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login